Enovis (ENOV) Gains from Investment Securities (2024 - 2025)
Enovis' (ENOV) quarterly Gains from Investment Securities came in at $1.8 million in Q4 2025, up 1900.0% year-over-year from $90000.0 in Q4 2024, and up 0.73% quarter-over-quarter from $1.8 million in Q2 2025.
Powered by 
Analysis
Enovis (ENOV) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Enovis (ENOV) has reported Gains from Investment Securities for 2 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 1900.0% year-over-year to $1.8 million in Q4 2025; TTM through Jul 2026 was $1.8 million, a 20.64% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 108.95% from the prior year.
- Gains from Investment Securities was $1.8 million for Q4 2025 at Enovis, up from $1.8 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $13.4 million in Q1 2024 and troughed at -$33.5 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.35 Bn | 175.75 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.64 Bn | 122.42 Bn | 1.96 Bn |
| 3 | Medtronic | 117.17 Bn | 108.35 Bn | 6.34 Bn |
| 4 | Stryker | 105.09 Bn | 101.62 Bn | 4.50 Bn |
| 5 | Boston Scientific | 64.76 Bn | 64.22 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.91 Bn | 45.66 Bn | 1.35 Bn |
| 7 | Alcon | 33.09 Bn | 31.64 Bn | 1.68 Bn |
| 8 | Dexcom | 32.24 Bn | 30.29 Bn | 830.00 Mn |
| 9 | Steris | 20.78 Bn | 20.30 Bn | 684.20 Mn |
| 10 | Enovis | 1.08 Bn | 1.06 Bn | 359.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 3, 2025 | 1.80 Mn |
| Apr 4, 2025 | 1.79 Mn |
| Dec 31, 2024 | -195,000.00 |
| Sep 27, 2024 | -100,000.00 |
| Jun 28, 2024 | -33.50 Mn |
| Mar 29, 2024 | 13.44 Mn |